ABOUT.
Multiomic is a next-generation precision medicine business, applying computational systems biology to develop and commercialize data assets for metabolic syndrome — the world’s largest healthcare burden. With our unique combination of data science and biology expertise, we are enabling data-driven development of therapeutics and are bringing understanding into complex biological systems.
Metabolic syndrome, a cluster of closely-related diseases (cardiovascular, diabetes, non-alcoholic liver disease, obesity) with many common risk factors, is costing the healthcare system $1 trillion in the US alone (forecast >$3 trillion by 2035), with 11x the number of patients worldwide. It is a 10x larger market than oncology, yet attracts only 40% of the VC dollars
CARDIOVASCULAR
The most common cause of death worldwide
DIABETES
Major impact on patients’ lifestyle and CVD risk
NON-ALCOHOLIC LIVER DISEASE
Metabolic disease without an efficient long-term treatment
OBESITY
Main risk factor for development of cardiometabolic diseases
OUR FOCUS.
A major unmet need is the lack of high-fidelity tools to focus the right treatments on the right patients. In oncology, treatments are personalized based on genetic and protein biomarkers whereas metabolic syndrome patients are being prescribed drugs based on their blood pressure, fasting glucose and cholesterol levels. As metabolic syndrome is a complex multifactorial condition, it requires systems medicine models and composite biomarkers that were hitherto infeasible. ML-enabled data science and rapidly-falling omics costs have changed the game and we are aiming at becoming the leader in this space
STATISTICS.
METABOLIC SYNDROME PANDEMIC
please view sidebar for data sources.
WHAT WE DO
MULTI Omic ANalysis.
GENOMICS
Genetic variants that influence the baseline risk for diseases
EPIGENOMICS
Regulation that defines the activity or inactivity of disease or protective gene variants
TRANSCRIPTOMICS
Gene activity and their unfolding into biological action in the body
PROTEOMICS
Proteins that drive protection from, response to and the development of the disease
METABOLOMICS
Intermediary metabolites that enlighten metabolic processes in health and disease
PHENOMICS
Physiological and morphological output of biology
UNDERSTANDING CHRONIC DISEASE BIOLOGY
EXPERTS IN THEIR FIELDS
OPERATING TEAM.
Robert Thong
CO-FOUNDER, Chairman & CEO
30+ years in biopharma and healthcare, with a strong focus on R&D strategy/management, B2B partnerships and enterprise value creation. Has engaged with 100+ organizations in biopharma, medical technology and healthcare. Published authority on biopharma R&D alliances and biotech business models
Slaven Stekovic
PRESIDENT & COO
Forbes 30under30. Founded a cellular ageing biotech startup (The Longevity Labs GmbH, whose award-winning nutraceutical is now marketed in >14 countries incl. US), exited after 3 years. Operational leadership roles at two other data-intensive startups in cancer genomics and AI-enabled robotics respectively
Cristina Balagué
HEAD OF DISEASE BIOLOGY
20 years of drug discovery program leadership. Experienced across multiple disease areas, from target validation to preclinical development and regulatory. Chaired new therapeutic program generation activities at Almirall, a leading European mid-sized pharma
Celia Antonio Schell
HEAD OF CLINICAL OPERATIONS
14 years experience in clinical research at Novartis and ICON (global CRO) including 10 years of managing international clinical studies. Most recent prior role was managing a global Phase III clinical study of >7,000 patients across 43 countries for a cardiovascular drug
Ariella Cohain
HEAD OF COMPUTATIONAL BIOLOGY
Deep technical capabilities, strong academic network and author of multiple scientific papers on system biology modeling of cardiometabolic diseases. Most recent prior role was leading a data science team at a Boston-based biotech that was acquired for >$2 billion
Andrew Parton
Lead DATA SCIENTIST
Accomplished systems biology modeler. Most recently at the European Bioinformatics Institute. Prior to this, conducted academic research and published on atherosclerosis modeling
Esra Berkol
CHIEF OF STAFF & MARKETING MANAGER
Broad experience base in collaborative contexts. Product manager in a B2B financial data & solutions provider. Project manager in an energy & fintech business. Has founded and exited her own business
Angelos Spiliopoulos
PROJECT MANAGER
Skilled analyst operating at the intersection of science and business. Two Masters degrees with Distinction in respectively, functional omics (metabolic syndrome major) and bioscience entreprise
Becky Cripps
BUSINESS & SCIENCE ANALYST
Analyst working across the bioscience and business interface with Master’s degree in Bioscience Entrepreneurship and Bachelor’s degree in biochemistry. Previous experience working in a range of healthcare-centred roles, spanning project support in primary care training to life sciences public relations
Henrietta Bull
MARKETING & BUSINESS ANALYST
Analyst working at the cross-section of business and bioscience, with an MSc in Bioscience Entrepreneurship and a BSc in Biomedical Sciences. Prior experience includes working in bioscience SMEs across marketing and business development functions, as well as pharmaceutical R&D
Contact.
Want to be a part of our team?
Got a partnership in mind?
Get in touch with us and know more about how we are changing the face of healthcare.
Multiomic Health Limited is a registered UK company
Company #13246608
70 White Lion St, London N1 9PP, UK
info@multiomic.health